Does venlafaxine decrease libido (sexual desire)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Venlafaxine Decrease Sexual Desire?

Yes, venlafaxine commonly causes decreased libido (sexual desire), with rates ranging from 38-50% in men and 26-32% in women, though it tends to cause less sexual dysfunction than some SSRIs like paroxetine.

Evidence from FDA Drug Label and Guidelines

The FDA drug label for venlafaxine explicitly lists "libido decreased" as an adverse event occurring in 2% of patients in controlled trials, compared to less than 1% with placebo 1. The label also documents other sexual side effects including abnormal ejaculation/orgasm (12% vs 2% placebo) and impotence (6% vs 2% placebo in men) 1.

American College of Physicians guidelines confirm that sexual adverse events are among the most commonly reported side effects with second-generation antidepressants, including venlafaxine 2. However, the guidelines note that absolute rates of sexual dysfunction are likely underreported in clinical trials 2.

Comparative Risk Among Antidepressants

Venlafaxine occupies a middle ground for sexual dysfunction risk:

  • Higher risk than: Bupropion, mirtazapine, nefazodone, moclobemide, and agomelatine
  • Lower risk than: Paroxetine (which has the highest rates among SSRIs) 2
  • Similar risk to: Other SSRIs like fluoxetine and sertraline

Research data shows venlafaxine causes sexual dysfunction in approximately 67% of patients when systematically assessed 3, with decreased libido specifically affecting 38-50% of men and 26-32% of women 4. These rates are substantially higher than the 2% reported in FDA trials, highlighting the underreporting issue mentioned in guidelines 2.

Clinical Implications

Key Points for Practice:

  • Proactively screen for sexual dysfunction before and during treatment, as patients often don't volunteer this information 4, 5
  • Sexual side effects are dose-dependent with venlafaxine—higher doses (particularly above 225 mg/day) increase risk 1
  • The serotonergic mechanism (predominant at lower doses) is primarily responsible for sexual dysfunction 6
  • Sexual dysfunction is a major cause of treatment non-compliance and can affect quality of life 7, 5

Management Strategy:

If decreased libido occurs on venlafaxine:

  1. First option: Consider switching to bupropion or mirtazapine, which have significantly lower rates of sexual dysfunction (6-24% vs 67%) 3, 6
  2. Second option: Reduce venlafaxine dose if clinically feasible
  3. Third option: Add bupropion as augmentation (though evidence is limited)

Important Caveat:

One study found an unexpected relationship where patients who responded well to antidepressant treatment reported less sexual dysfunction 4. This suggests that untreated depression itself contributes to sexual problems, and successful treatment may partially offset medication-induced effects. However, this doesn't negate the direct pharmacological impact on sexual function.

Bottom Line

Venlafaxine does decrease sexual desire through its serotonergic activity, affecting approximately one-third to two-thirds of patients depending on assessment method 4, 3. While less problematic than paroxetine, it causes substantially more sexual dysfunction than alternatives like bupropion or mirtazapine 2, 3, 6. Direct questioning using standardized tools is essential since passive reporting underestimates the true incidence by 10-fold 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.